TB-500
low riskAlso: Thymosin Beta-4 · Tβ4 · Thymobeta-4
Thymosin Beta-4 (TB-500 is the synthetic fragment) has potent tissue repair, anti-inflammatory, and angiogenic properties. Human Phase II trials exist for cardiac repair and wound healing. WADA-prohibited due to performance-enhancing potential.
Reported Benefits
Wound healing
Human Phase II trials in chronic dermal wounds show accelerated closure.
Cardiac repair
Phase II trial showed improved cardiac function post-MI.
Anti-inflammatory
Reduces TNF-α, IL-1β in multiple models.
Mechanism of Action
Sequesters G-actin; upregulates VEGF, MMP-2, KGF-1; promotes stem cell differentiation and mobilization to injury sites.
Key Clinical Studies
Sosne et al. (2010)
RCT · Phase II
Improved wound healing in chronic dermal wounds
Human Evidence Context
Unlike most research peptides, TB-500/Thymosin Beta-4 has completed Phase II clinical trials for cardiac indications and wound healing, giving it one of the more credible human evidence bases in the non-approved peptide space.
WADA Prohibition
TB-500 is on the World Anti-Doping Agency’s prohibited list — itself a signal that WADA considers the performance-enhancing potential real enough to regulate.
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Fatigue (loading phase)
- •Injection site reactions
- •Headache
Contraindications
- •Active malignancy
- •Pregnancy
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe TB-500?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →